Search results
Results From The WOW.Com Content Network
This registry based, multi-center, multi-country data provide provisional support for the use of ECMO for COVID-19 associated acute hypoxemic respiratory failure. Given that this is a complex technology that can be resource intense, guidelines exist for the use of ECMO during the COVID-19 pandemic. [85] [86] [87]
Extracorporeal membrane oxygenation (ECMO), is a form of extracorporeal life support, providing prolonged cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of oxygen, gas exchange or blood supply to sustain life.
For premium support please call: 800-290-4726 more ways to reach us
Once the patient is stabilised on the ECMO circuit, they are transferred for further management of causal pathology, for example to the cardiac catheterisation laboratory for coronary angiogram or to radiology for thrombectomy. In an effort to avoid limb ischaemia, in some centres a third cannula is inserted.
In September 2020, the outcomes of 1,035 COVID-19 patients supported with ECMO from 213 experienced centers in 36 different countries were published in The Lancet, and demonstrated 38% mortality, which is similar to many other respiratory diseases treated with ECMO. [12]
Robert Bartlett (born May 8, 1939) is an American physician and medical researcher who is credited with developing a lifesaving heart-lung technology known as extracorporeal membrane oxygenation (ECMO). He is an emeritus professor of surgery at the University of Michigan Medical School.
Pierre Kory is an American critical care physician who gained attention during the COVID-19 pandemic for advocating widespread off-label use of certain drugs as treatments for COVID-19, as president and co-founder of the Front Line COVID-19 Critical Care Alliance (FLCCC). [1] [2] Kory testified twice to the U.S. Senate regarding COVID-19
In the United States, remdesivir is indicated for the treatment of COVID‑19 in people 28 days of age and older and weighing at least 3 kilograms (6.6 lb) who are hospitalized; or not hospitalized and have mild-to-moderate COVID‑19, and are at high risk for progression to severe COVID‑19, including hospitalization or death. [12] [26]